New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Abstract
Background Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions...
Paper Details
Title
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Published Date
Jan 1, 2009
Journal
Volume
45
Issue
2
Pages
228 - 247
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History